Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
René RettlChristopher MannFranz DucaTheresa-Marie DachsChristina BinderLuciana Camuz LigiosLore SchrutkaDaniel DalosMatthias KoschutnikCarolina DonàAndreas Anselm KammerlanderDietrich BeiztkeChristian LoeweSilvia Charwat-ReslChristian HengstenbergJohannes KastnerRoza Badr EslamChristina Binder-RodriguezPublished in: European heart journal. Cardiovascular Imaging (2021)
Tafamidis delays myocardial amyloid progression in ATTR-CM patients, resulting in structural, functional, and clinical benefits compared to the natural course. Serial CMR including measurement of ECV may be appropriate for disease-specific therapy monitoring.